Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
BeOne terminates a MUC1-targeting project.
A binary Xpovio catalyst is set for March.
Welireg, Padcev, and a surprise fillip for Flare.
AZD0120’s first pivotal trial will test settings as early as the second line.
Two new pivotal Chinese first-line trials have started in lung cancer.
The company will start a phase 2/3 trial of PF-08634404 in March.
